Table 2 Treatment outcome at month 6 and 12 in relation to the nucleoside analogue used

Baseline^a

874

467/874; 53.4%

362/874; 41.4%

44/874; 5.0%)

NA

Month 6^b

743/874; 85.1%

391/467; 83.7%

313/362; 86.5%

39/44; 88.6%

0.591

 with VL; still on treatment

676/743; 91.0%

350/391; 89.5%

288/313; 92.0%

38/39; 97.4%

0.225

 VL > 150^c

90/676; 13.3%

52/350; 15.0%

34/288; 11.8%

4/38; 10.5%

0.956

 VL > 1000^c

57/676; 8.4%

34/350; 9.7%

19/288; 6.6%

4/38; 10.5%

0.957

 Died or LTFU

131/874; 15.0%

77/426; 18.1%

49/337; 14.5%

5/38; 13.2%

0.912

 Died or LTFU + VL > 150^c

221/807; 27.4%

129/426; 30.2%

83/337; 24.6%

9/43; 20.9%

0.731

 Died or LTFU + VL > 1000^c

188/807; 23.3%

111/426; 26.0%

68/337; 20.2%

9/43; 20.9%

0.773

Month 12^b

690/874; 78.9%

364/467 77.9%

289/362; 79.8%

37/44; 84.1%

0.730

 with VL; still on treatment

459/690; 66.5%

219/364; 60.2%

207/289; 71.6%

33/37; 89.2%

0.006

 VL > 150^#

61/459; 13.3%

30/219; 13.7%

27/207; 13.0%

4/33; 12.1%

1.000

 VL > 1000^c

34/459; 7.4%

19/219; 8.7%

13/207; 6.3%

2/33; 6.1%

0.989

 Died or LTFU

184/874; 21.1%

103/322; 32.0%

73/280; 26.1%

7/40; 17.5%

0.654

 Died or LTFU + VL > 150^c

245/643; 38.1%

133/322; 41.3%

100/280; 35.7%

11/40; 27.5%

0.623

 Died or LTFU + VL > 1000^c

218/643; 33.9%

122/322; 37.9%

86/280; 30.7%

9/40; 22.5%

0.550